Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $706.40M
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -73.79%
• EPS Growth: -5.24%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 138,238,000
• 10 Day Avg. Volume: 1,188,906
• 30 Day Avg. Volume: 1,242,748
• PEG Ratio: -1.47
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 2.10
• Enterprise Value/Market Cap: 3.73
• Enterprise Value/Revenue: 10.78
• Enterprise Value/Gross Profit: 195.51
• Enterprise Value/Ebitda: -1.20
• 1Y Price Target: $18.14
• Price Target Upside: 234.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 50 Neutral
• Price Target: $5.50 ▲(1.29%Upside)

Vir Biotechnology's overall score reflects financial volatility and strategic challenges. The company's strong cash position and advancements in disease programs offer potential for future growth, but current financial instability and reliance on partnerships pose significant risks.

Positive Factors

Financial Health and Investment Potential

With approximately $1.02B in cash and runway into mid-2027, full ownership of its key assets, and catalysts across both CHD and oncology, Vir is entering a more focused and potentially more investable phase of its lifecycle.

Hepatitis Delta Virus Market Opportunity

The focus on the Hepatitis Delta Virus program indicates a strong potential market opportunity.

Oncology Program Progress

Vir's T-cell engager (TCE) in oncology programs are progressing well, with VIR-5818 and VIR-5500 showing early efficacy and safety signals in solid tumors.

Negative Factors

Competitive Positioning in Oncology

Pasritamig's safety profile could challenge VIR-5500's competitive positioning, with only 9% Grade 1 CRS at RP2D compared to VIR-5500's 25% low-grade CRS rate.

HBV Program Challenges

The updated 24-week off-treatment data from the Phase 2 program (MARCH) did not meet functional cure thresholds needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus (CHB).

Partnership Difficulties

The prospects for a larger HBV partnership could be more challenging due to the recent data results.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc. is a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. It operates within the biotechnology sector, primarily targeting viral infections such as influenza, hepatitis B, and COVID-19. The company specializes in developing innovative therapeutics, including monoclonal antibodies, small interfering ribonucleic acid (siRNA), and vaccines aimed at enhancing the immune system's ability to combat these diseases.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often include licensing agreements, milestone payments, and royalty revenues based on the successful development and commercialization of its therapeutic candidates. The company also seeks government grants and contracts to support its research and development efforts. For instance, Vir has entered into significant collaborations with companies like GlaxoSmithKline (GSK) to develop and commercialize antibodies for infectious diseases, including COVID-19 therapies. Revenue is also expected to be generated through the eventual sales of its proprietary products once they receive regulatory approval and are commercialized.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology shows financial volatility with declining revenue and profitability. The balance sheet remains relatively strong due to low leverage, but cash flow challenges highlight potential liquidity concerns. The company needs to stabilize its revenue and improve operational efficiencies to enhance financial performance.

Income Statement

Vir Biotechnology experienced significant revenue fluctuations, with a sharp decline from 2022 to 2023 and further into TTM (Trailing-Twelve-Months). The gross profit margin has decreased substantially, and the company recorded negative EBIT and net profit margins in recent periods, reflecting financial instability. Despite past profitability, recent performance indicates challenges in maintaining revenue and controlling costs.

Balance Sheet

The company maintains a solid equity position with a strong equity ratio, indicating financial stability. The debt-to-equity ratio is low, suggesting prudent leverage use. However, declining assets and equity from 2022 to TTM show potential risks if revenue and profitability do not improve.

Cash Flow

Operating cash flow has deteriorated significantly, leading to negative free cash flow in recent periods. The negative free cash flow to net income ratio suggests challenges in generating cash from operations. Despite high cash reserves, the negative trends in cash flow metrics indicate potential liquidity issues if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.62M	74.20M	86.18M	1.58B	1.09B	67.25M
Gross Profit	13.48M	73.36M	83.42M	1.43B	1.02B	-234.33M
EBITDA	-594.54M	-537.61M	-664.85M	833.07M	420.75M	-289.80M
Net Income	-577.65M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.31B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	801.66M	990.38M	1.52B	2.40B	708.14M	736.86M
Total Debt	96.09M	97.89M	124.54M	127.97M	133.56M	66.56M
Total Liabilities	263.91M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	1.04B	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-422.14M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-415.08M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	597.76M	499.37M	164.63M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.83M	4.39M	7.48M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.43
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 5.43 is above the 20-day moving average (MA) of 5.24, above the 50-day MA of 5.28, and below the 200-day MA of 7.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.01 is Neutral, neither overbought nor oversold. The STOCH value of 55.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	59 Neutral	$1.02B	―	-57.92%	―	-13.37%	2.57%
NRIX	56 Neutral	$892.72M	―	-64.16%	―	-30.25%	-5.92%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
VIR	50 Neutral	$706.40M	―	-44.59%	―	-73.79%	-5.24%
RCUS	48 Neutral	$885.20M	―	-63.17%	―	-40.51%	-35.07%
SYRE	43 Neutral	$934.88M	2.31	-50.47%	―	-100.00%	94.68%
PHVS	42 Neutral	$940.01M	―	-51.85%	―	―	0.71%

Vir Biotechnology Corporate Events

Vir Biotechnology Holds 2025 Annual Stockholder Meeting

On May 29, 2025, Vir Biotechnology, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class III directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (VIR) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data

On May 9, 2025, Vir Biotechnology announced 24-week post-treatment data from its MARCH Phase 2 study on tobevibart and elebsiran for chronic hepatitis B, presented at the EASL Congress in Amsterdam. The study showed HBsAg loss in 17% and 21% of participants with low baseline HBsAg levels, using the combination with or without pegylated interferon alpha. Despite the promising results, Vir has not secured a development partner for further Phase 3 trials and will streamline the final stages of the Phase 2 study, aligning with its focus on the ECLIPSE Phase 3 program for hepatitis delta and oncology initiatives. The company maintains its cash runway guidance into mid-2027.